ACQUISITIONS, DIVESTITURES AND LICENSING ARRANGEMENTS (Tables)

12 Months Ended

Dec. 31, 2019

Acquisitions and Divestitures [Abstract]

Schedule of Consideration Transferred [Table Text Block]

The total consideration for the acquisition consisted of the following:

Amounts in Millions, Except Per Share Data	Total Consideration
Celgene shares outstanding at November 19, 2019	714.9
Cash per share	$	50
Cash consideration for outstanding shares	35,745
Celgene shares outstanding at November 19, 2019	714.9
Closing price of BMS common stock on November 19, 2019	$	56.48
Estimated fair value of share consideration	40,378
Celgene shares outstanding at November 19, 2019	714.9
Closing price of CVR(a)	$	2.30
Fair value of CVRs	1,644
Fair value of replacement options	1,428
Fair value of replacement restricted share awards	987
Fair value of CVRs issued to option and share award holders	87
Fair value of share-based compensation awards attributable to pre-combination service(b)	2,502
Total consideration transferred	$	80,269

(a) The closing price of CVR is based on the first trade on November 21, 2019.

(b)

Fair value of the awards attributed to post-combination services of $1.0 billion will be included in compensation costs. Refer to “—Note 18. Employee Stock Benefit Plans” for more information.

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The preliminary purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the Acquisition Date based upon their respective preliminary fair values summarized below:

Dollars in Millions	Preliminary Purchase Price Allocation
Cash and cash equivalents	$	11,179
Receivables	2,652
Inventories	4,511
Property, plant and equipment	1,342
Intangible assets(a)	64,027
Otezla* assets held-for-sale(b)	13,400
Other assets	3,408
Accounts payable	(363		)
Income taxes payable	(2,718		)
Deferred income tax liabilities	(7,339		)
Debt	(21,782		)
Other liabilities	(4,017		)
Identifiable net assets acquired	64,300
Goodwill(c)	15,969
Total consideration transferred	$	80,269

(a) Intangible assets consists of currently marketed product rights of approximately $44.5 billion (amortized over 5.1 years calculated using the weighted-average useful life of the assets) and IPRD of approximately $19.5 billion (not amortized), and were valued using the multi-period excess earnings method. This method starts with a forecast of all of the expected future net cash flows associated with the asset and then involves adjusting the forecast to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams.

(b) Amount includes $381 million of inventory, $13.0 billion of developed product rights, $19 million of accrued liabilities and $5 million of other non-current liabilities. Refer to “—Divestitures” for more information.

(c) Goodwill represents the going-concern value associated with future product discovery beyond the existing pipeline and expected value of synergies resulting from cost savings and avoidance not attributed to identifiable assets. Goodwill is not deductible for tax purposes.

Business Acquisition, Pro Forma Information [Table Text Block]

	Year Ended December 31,
Amounts in Million	2019		2018
Total Revenues	$	39,759	$	36,243
Net Earnings/(Loss)	3,369		(4,083		)

Divestitures [Table Text Block]

Divestitures

The following table summarizes the financial impact of divestitures including royalties, which are included in Other (income)/expense, net. Revenue and pretax earnings related to all divestitures and assets held-for-sale were not material in all periods presented (excluding divestiture gains or losses).

	Proceeds(a)						Divestiture Gains									Royalty Income
Dollars in Millions	2019		2018		2017		2019			2018			2017			2019			2018			2017
Otezla*	$	13,400	$	—	$	—	$	—		$	—		$	—		$	—		$	—		$	—
UPSA Business	1,508		—		—		(1,157		)	—			—			—			—			—
Diabetes Business	661		579		405		—			—			(126		)	(650		)	(661		)	(329		)
Erbitux* Business	15		216		218		—			—			—			(23		)	(145		)	(224		)
Manufacturing Operations	48		160		—		1			—			—			—			—			—
Plavix* and Avapro*/Avalide*	—		80		—		—			—			—			—			—			—
Investigational HIV Business	—		—		—		—			—			(11		)	—			—			—
Mature Brands and Other	10		212		28		(12		)	(178		)	(24		)	(13		)	(8		)	(4		)
Total	$	15,642	$	1,247	$	651	$	(1,168	)	$	(178	)	$	(161	)	$	(686	)	$	(814	)	$	(557	)

(a) Includes royalties received subsequent to the related sale of the asset or business.